StreetAlpha.app
Home › Stocks › RCKT

Rocket Pharmaceuticals, Inc. (RCKT)

Healthcare
$2.11
▼ −2.31%
LAST CLOSE · NOV 17

Rocket Pharmaceuticals develops gene therapies for rare inherited heart diseases. It last closed at $2.11 on Nov 17, down 2.31% on the day. The average 12-month price target from 5 analysts is $8.60 (+307.6% from the last close), with a high of $15.00 and a low of $4.00. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell).

AI Auto Pilots
Is RCKT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$16.2M
EPS (diluted)
−$0.15
Free cash flow
−$159.2M
Valuation
Market cap
$235.6M
111.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$95.5M
At Sep 30
Debt
$30.4M
At Sep 30
Shareholder equity
$326.7M
Shares outstanding
111.7M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From RCKT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
5firms
3 Buy2 Hold0 Sell
Each firm's latest rating on RCKT in the past 90 days
Average 12-month target
$8.60
▲ 307.6% upside

Based on 5 analysts who set a price target on RCKT in the past 90 days. The average target is $8.60, with a high of $15.00 and a low of $4.00, compared with the last close of $2.11.

Low $4.00Avg $8.60High $15.00
Blue marker: last close $2.11
Highest target$15.00
Average target$8.60
Lowest target$4.00
Latest rating changes
Goldman SachsUpgrade
Oct 8Hold$4
Leerink PartnersMaintained
Oct 7Hold$4
WedbushReiterated
Sep 16Buy$15
NeedhamUpgrade
Sep 16Buy$9
Chardan CapitalMaintained
Sep 1Buy$11
DateFirmActionRatingPrice target
Oct 8Goldman SachsUpgradeHold$4
Oct 7Leerink PartnersMaintainedHold$4
Sep 16WedbushReiteratedBuy$15
Sep 16NeedhamUpgradeBuy$9
Sep 1Chardan CapitalMaintainedBuy$11
Loading…

Technical Analysis

RCKT · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 14% below its 20 day and 25% below its 50 day average. It is 60% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the 52 week low at $2.03, and the nearest resistance the Pivot R1 at $2.19.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.5%/day
Key levels
$5.4552 week high+158.3%
$3.38200 day average+60.2%
$3.11100 day average+47.4%
$2.6550 day average+25.6%
$2.4020 day average+13.7%
$2.38Swing high (Oct 21)+12.8%
$2.19Pivot R1+3.8%
$2.11Pivot+0.0%
$2.11Last close
$2.0352 week low−3.8%
$2.03Pivot S1−3.8%
Indicators
RSI (14)35.59Weak, oversold below 30Neutral
MACD-0.10Below its signal lineBearish
Stochastic12.2Near the bottom of its rangeOversold
ADX (14)16.2No clear trend
Williams %R-87.5Oversold below −80, overbought above −20Oversold
CCI (20)-169.8Oversold below −100, overbought above 100Oversold
Rate of change−15.9%Change over 10 sessionsBearish
ATR (14)$0.18Typical daily range, 8.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RCKT

What happened before

See how RCKT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RCKT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RCKT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RCKT in the last 90 days.

Loading…

See today’s whale options flow across the market →

RCKT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼70 buying vs 104 selling
  • ▼Held by funds -4.3 pts
  • ▼Funds holding -19
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding174193−9.8%
In funds' top 10110.0%
Held by funds86.5%90.8%−4.3 pts
New / increased18 / 5219 / 73−23.9%
Reduced / sold out67 / 3765 / 34+5.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RCKT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCKT is in one of them and how their past RCKT trades turned out.

RCKT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RCKT in an article yet. Here's the latest on the wider market.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals is a biotechnology company based in New York that develops gene therapies for rare inherited diseases. Its main focus is heart conditions caused by genetic mutations, such as certain forms of cardiomyopathy. The company uses modified viruses that do not cause disease to deliver working copies of genes into patients' cells. Its treatments are aimed at patients with rare conditions, and the company works with healthcare providers, payors and patient communities.

Headquarters
New York, NY